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Abstract
Background: While the social, ethical, and legal implications of biobanking and large scale data sharing are already
complicated enough, they may be further compounded by research on the human microbiome.
Discussion: The human microbiome is the entire complement of microorganisms that exists in and on every
human body. Currently most biobanks focus primarily on human tissues and/or associated data (e.g. health
records). Accordingly, most discussions in the social sciences and humanities on these issues are focused
(appropriately so) on the implications of biobanks and sharing data derived from human tissues. However, rapid
advances in human microbiome research involve collecting large amounts of data on microorganisms that exist in
symbiotic relationships with the human body. Currently it is not clear whether these microorganisms should be
considered part of or separate from the human body. Arguments can be made for both, but ultimately it seems
that the dichotomy of human versus non-human and self versus non-self inevitably breaks down in this context.
This situation has the potential to add further complications to debates on biobanking.
Summary: In this paper, we revisit some of the core problem areas of privacy, consent, ownership, return of
results, governance, and benefit sharing, and consider how they might be impacted upon by human microbiome
research. Some of the issues discussed also have relevance to other forms of microbial research. Discussion of
these themes is guided by conceptual analysis of microbiome research and interviews with leading Canadian
scientists in the field.
Keywords: human microbiome, health research, consent, privacy, ownership, return of results, policy, biobanks,
ELSI, research ethics
Background
Biobanks, loosely defined as large collections of biologi-
cal tissues samples, often with some degree of linked
clinical or medical information, have received consider-
able attention in the ELSI (ethical, legal, social issues of
genome research) and scientific literature in recent years
[1-3]. This attention is due not just to the complexity of
the issues raised by biobank related research, but also
because they call into question established research
ethics norms and accepted practices[4]. The nature of
these ethical conundrums has been well documented,
with research focused on issues such as privacy,
informed consent, ownership of samples and informa-
tion, secondary use of biological specimens, benefit shar-
ing and governance [5-8]. While these biobank issues
remain problematic and unresolved, other areas of
science are moving ahead rapidly, and have the potential
to further complicate matters[9]. In particular, this
paper considers recent large scale research efforts
towards studying the human microbiome, and the
potential social and ethical implications of this research
for biobanks.
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bial and human cells, a ‘super-organism’ [10] containing
over 100 trillion microbiota that are essential for nutri-
tion, immunity and pathogen resistance[11]. Whilst some
are harmful, the majority of human cell and microbial
cell interactions are mutually beneficial, and essential to
human physiologic functions and day to day activities
[12]. Research on the human microbiome aims to eluci-
date the relationship between human health, physiology,
and behaviour and the various microbial communities
present in different areas of our body (including the
mucosa, gastrointestinal tract, urogenital system and
skin)[13,14]. The goal of the Human Microbiome Project
(HMP), established in 2007, is to characterize the role of
microbiota in human health and disease. More specifi-
cally, the HMP investigates such basic science questions
as whether humans share a common core microbiome
and whether particular changes in the human micro-
biome lead to changes in human health and disease states
(http://nihroadmap.nih.gov/hmp/)[15]. It is hoped that
this research will lead to benefits such as: a better under-
standing of human nutritional requirements (including
how individuals will respond to specific diets), resulting
in innovative food production and distribution strategies
[10,16,17] and other public health benefits[18,19];
increased knowledge of areas amenable to microbial
transplantation and successful manipulation[11]; forensic
tools[20,21]; and pharmaceutical improvements known
as ‘pharmacomicrobiomics’[17,22].
Human microbiome research, in and of itself, raises a
number of ethical, legal and social considerations[23].
However, the specific focus of this paper is how these
concerns overlap with those debated in the biobank lit-
erature and we therefore confine our discussion to
issues relevant to this particular context. The types of
information and samples collected by different biobanks
vary, but with increasing research efforts pertaining to
the human microbiome, it is inevitable that an increas-
ing number of biobanks will include collection of speci-
mens required for genomic studies of microbiota
associated with humans. To date there has been little
attention as to how human microbiome research may
affect or further compound the issues debated in the
context of biobanks. It is the purpose of this paper to
begin to investigate and discuss some of these questions.
Our discussion is informed by both the scientific lit-
erature on human microbiome research and the ELSI
literature on biobanks. Most importantly, though, we
draw on a series of 45 in-depth interviews that were
conducted by K.O. in 2009 to 2011. These semi-struc-
tured interviews consisted of a series of open-ended
questions on the topic of the social and ethical implica-
tions of the HMP, and were conducted either in-person,
or over the phone. Interview participants were
researchers working on the Canadian Microbiome
Initiative, and were invited to participate based on satis-
fying any of three criteria: (i) currently funded to con-
duct research on the human microbiome; (ii) attendance
at a meeting hosted by the Canadian Institutes of Health
Research (CIHR) in 2008, the purpose of which was to
discuss the form funding for the Canadian Microbiome
Initiative would take; (iii) referral based on expertise in
a particular aspect of research relevant to the social and
ethical aspects of the HMP. Taken together, intervie-
wees represented multidisciplinary expertise on the
range of body sites being targeted for study in the HMP,
and a spectrum of basic and applied researchers as well
as clinicians. The content of individual interviews
reflected the particular expertise of the interviewee, and
included the subject areas described in the discussion
below. Where possible, the discussion that follows is
based on peer-reviewed published literature, often sug-
gested by interviewees. Where research is novel or in
progress, we rely on anonymized statements of our
expert informants to illustrate specific arguments made
i nt h ed i s c u s s i o n .I ti si m p o r t a n tt on o t et h a ts o m eo f
the ethical issues we raise here are relevant to research
other than biobank studies. Conversely, there are many
other ethical issues related to human microbiome
research that are beyond the scope of this paper. We
therefore limit our discussion to those ethical issues
raised by human microbiome research that intersect
with biobank related issues.
Biobank discussions gravitate toward four issues that
are now well recognized in the ELSI literature on bio-
banks: privacy, consent, ownership, and return of
research results. Below, we discuss each of these issues
in turn, beginning with a brief outline of the problem as
currently recognised in the ELSI literature on biobanks,
followed by a discussion of the potential implications of
human microbiome research on the problem. In this
discussion, we pay particular attention to how the social
and ethical aspects of biobanks may change or become
further compounded as a consequence of microbiome
research being conducted using biobank type platforms
(see Table 1 for a summary of the issues and concerns
raised by biobanks relative to new issues introduce by
human microbiome research). We conclude with some
recommendations for policy and a consideration of
implications for benefit sharing and governance in this
evolving field.
Discussion
Privacy
The ability to protect both clinical and genetic data
stored in biobanks has been pivotal to biobank discus-
sion since such research was conceived[24]. Due to the
potentially sensitive nature of such data, there has been
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breaches, resulting in personal information being mis-
used[25]. This is of particular relevance in the context
of genetic data, as access to an individual’sb i o l o g i c a l
specimens and DNA may reveal sensitive information
such as predispositions to certain diseases, as well as
identity and ethnic background[26]. In spite of increas-
ing recognition that absolute guarantees of privacy pro-
tection can no longer be made[27,28], biobanks that
have been constructed in ethically sustainable ways go
to considerable effort to ensure that personal data is
adequately protected to avoid potential discrimination
or other adverse events[29].
These concerns are further compounded given recent
advances in human microbiome research such as that
‘microbial fingerprints’ have been found to be poten-
tially as individual as DNA or actual fingerprints. More
specifically, the composition of bacterial communities
associated with human skin have been found to be
unique to each individual, allowing for identification of
individuals through analysis of residual skin bacteria
recovered from an object (e.g. keyboard or mouse)
touched by that person[21]. The identification of an
individual by their microbial fingerprint potentially
raises privacy concerns similar to those already recog-
nised in genetic and biobank related research. How-
ever, the privacy concerns in microbiome research may
be somewhat more complex, primarily due to our lim-
ited understanding of the relevance of such informa-
tion at the current time. For example, microbiome
technology may allow access to information such as
past exposures, or locations an individual has visited in
the past (interview 132). As such information is not
available from analysis of human DNA alone, this may
constitute a very powerful new analytical dimension
for use in forensic investigations or by law enforce-
ment or homeland security agencies. Such possibilities
p r o m i s et ob eh i g h l yc o n t r o v e r s i a lg i v e nt h et e n s i o n s
that already exist between safe-guarding the integrity
of health research databases versus pressure from law
enforcement agencies to permit greater powers in the
use of DNA technologies and databases. Further con-
founding this, in contrast to DNA, the stability of
microbial fingerprints over time is unknown, so it is
not possible to say whether such information may be
linked to a specific individual for an indefinite period
of time (interview 142 & 131).
From a clinical perspective, human microbiome
research is still in its infancy, and it will take some time
to fully understand the meaning of microbiome findings
both on their own, and in the context of other relevant
genetic and health information. Similar to concerns with
the clinical validity of genome wide association studies
[30], there is concern that microbiome research data
may be prematurely or incorrectly interpreted. Similar
to human genetic information, microbial data may be
used, correctly or incorrectly, to reveal an individual’s
predisposition to certain conditions such as obesity[31].
One can conjecture that human microbiome data even
has the potential to reveal an individual’s socioeconomic
background. Perhaps more significantly, microbiome
information, when used in conjunction with genetic
information, may tell us a significant amount about a
certain individual’s susceptibility and predispositions and
would be more personally identifying than genetic data
alone[11]. For example, asthma is known to be a
Table 1 ELSI Issues Raised by Microbiome Research relative to Biobank and Related Studies
ELSI Consideration Nature of concern New issues introduced by HMB research
Privacy and
Confidentiality
- Discrimination and stigmatisation - Increased scope of disease predisposition
testing
- Microbial fingerprints
- Potential knowledge of past exposures
￿ For example, predisposition and susceptibility testing
Consent - Respecting autonomy
- Invasiveness of sample collection
- Cultural and personal acceptability of research
￿ E.g., research participation of minors (e.g. newborn blood spot collection) - E.g., Vaginal and fecal sample collection
Ownership - Human dignity
- Benefit sharing
- Samples traditionally considered waste, such
as fecal matter
￿ E.g., ownership of blood/tissue samples and cell lines - E.g., fecal transplant
Return of Results - Clinical validity
- ‘right to know’ versus ‘right not to know’
- Additional treatment and screening
possibilities
Biobank Governance - Public trust and consideration of societal viewpoints - Infectious disease
￿ E.g., ensuring minority viewpoints are considered
Justice - Resource allocation - Global health
￿ For example, payment and health insurance coverage of genetic tests
and pharmacogenomics
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mental causative factors[32]. Similarly, a typical micro-
bial signature has been identified for inflammatory
bowel disease (albeit with a non specific association)
(interview 135). A future doctor’s visit might therefore
conceivably involve both analysis of an individual’s
human genomic and microbial genomic profile[33].
Knowledge of both would potentially enable greater pre-
dictive value than genetics alone of what conditions may
develop in an individual’s lifetime. Just as with genetic
data there are fears of discrimination based on life
expectancy or job prospects, for example by employers
or insurance companies, and one can conjecture that
such microbiome-based discrimination may be more
disturbing, as there is potential for discrimination or
stigmatisation based on socio economic status, where an
individual was born and raised, and which countries an
individual has visited[23]. More worrying still, given that
we do not know what degree and depth of personal
information might be revealed through human microbial
analysis, it has been suggested that in some societies
such discrimination may even occur on supposed class
or caste basis (interview 132). On the other hand, it is
also possible that microbiome research may help to
counter stigma in some groups. For example, the identi-
fication of a microbial predisposition to obesity[34] may
lead to greater acceptance and understanding of indivi-
duals with obesity. However, it is quite unclear at this
point in time in which direction broader public and
institutional understandings will develop.
Consent
The issue of consent in biobank research has been well
characterized and discussed. The crux of the concern
relates to the ability of a potential research participant
to give truly informed consent for a research project in
which potential outcomes and effects are unknown,
and when the precise nature of future research to be
conducted may not yet be conceived[35-39]. Many of
these concerns remain similar in the context of micro-
biome research, where individuals may be asked to
give specimens to be deposited in research banks for
an indefinite period of time and for an undefined or
loosely defined purpose. This raises questions regard-
ing the integrity of the informed consent procedure,
potentially leading to the erosion of research subjects’
protection and an individual’s autonomy in decision
making about research participation[6,40]. Biobank
debates have suggested a number of proposed solu-
t i o n st ot h i si s s u e ,i n c l u d i n g broad consent, requiring
re-consenting on a regular basis, and adaptive govern-
ance mechanisms that allow for representative deci-
sion-making on behalf of large numbers of biobank
research participants [41,42].
Concerns about consent, as they relate to biobanks,
have important implications for microbiome research,
both in terms of outlining potential challenges, and in
suggesting possible resolutions such as those outlined
above. An area in which this is particularly notable is
that of child involvement in health research, with ques-
tions being raised as to the ethics of children becoming
research subjects when they cannot give informed con-
sent[43-46]; for example, infant stool sample collection
for microbial research raises similar concerns to new
born blood spot collection in genetic biobank research.
Moreover, concerns regarding data-sharing may be simi-
lar for both microbial and human specimens, in that
once samples are shared with other researchers it
becomes difficult to regulate or withdraw consent. How-
ever, it is important to note that it is possible that
microbial research may not be any more ethically pro-
blematic than genetic research if microbial data are not
stable over time. There is currently scientific uncertainty
and disagreement as to the relative stability of an indivi-
dual’sm i c r o b i o m eo v e rt i m ea n dt h ed e g r e et ow h i c h
an individual’s human genome predetermines their
microbiome. If it turns out that there is significant varia-
tion over a life-span, and/or a low degree of genetic pre-
determination then, for example, a child whose micro-
bial sample was collected in neonatal life may not be
identifiable from the specimen over the long term.
In considering current biobanking practices and the
potential compounding of ethical implications owing to
microbiome research, an important factor that needs to
be considered relates to the individual subjective and
cultural acceptability of the actual research. For exam-
ple, biobank research often involves use of a point in
time biological specimen, such as a pathology related
tissue sample, blood draw or buccal swab. Such sample
collection is usually relatively benign, painless and may
not require any additional procedures other than what
is clinically required. However, microbial research may
be considered more invasive, or less culturally accepta-
b l eb ys o m eg r o u p s .M o s tn o t a b l y ,c o l l e c t i o no fs t o o l
samples or vaginal swabs may not be acceptable to
some individuals, or in some countries or ethnic groups
(interview 139). This is further exacerbated by the possi-
ble need for collection from multiple orifices, and multi-
ple collections over time. Certainly the nature of the
research needs to be clearly outlined for an individual to
give informed consent for a research study. However it
is not unreasonable to conjecture that if some types of
research are not acceptable to certain groups, these
groups may not participate in research studies, resulting
in research findings that are relevant to only certain
sub-sectors of society. While this concern is not unique
to microbial research, it seems that biobank studies that
also investigate aspects of the human microbiome
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approval, trust and commitment to the research
enterprise.
Ownership
As alluded to above, microbial specimens may be col-
lected from a number of different collection sites includ-
ing the nose, mouth, gastrointestinal tract, skin, and
urogenital tract (http://nihroadmap.nih.gov/hmp/). As
with human biological specimen collection, microbial
sample collection may be more or less invasive. How-
ever, microbiome research differs somewhat in that
some microbial samples are generally considered waste
(such as dead skin or feces). Interestingly, the question
of ownership arises, a topic that has already led to con-
siderable debate within the biobank literature. In parti-
cular, there is debate as to whether a biological
specimen, such as tissue, a tumour or blood in some
way ‘belongs’ to the individual it came from, at least for
a defined period of time. Irrespective of whether one
considers tissue that has been removed from an indivi-
d u a lt ob eo w n e db yt h e ma ta n yg i v e nt i m ei nt h e
future, at the very least current thinking tends towards
informed consent being required not only for removal
of a biological specimen, but also for its use in research.
A case illustrative of the controversy in this context is
that of Henrietta Lacks, an African American woman
whose tumour cells were used in medical research to
create profitable immortal cell lines without her knowl-
edge or consent[47]. This case raises questions not just
about the extent of ownership, but also the potential for
future benefit sharing. In particular, discrepancies have
been pointed out between the large profits made by
companies using Lacks’ cell lines and the family and
descendants of Henrietta Lacks, who in many cases can-
not afford health insurance.
T h eq u e s t i o no fo w n e r s h i pm a yb e c o m ee v e nm o r e
complex with microbial research. This is particularly the
case with research on the gastro intestinal microbiome,
which relies heavily on the use of fecal samples. In other
words, the question of ‘who owns your poop?’ now
becomes relevant. The question is complex not only
because feces has traditionally been considered to be
waste, but because of the ambiguous relationship
between the genomes of commensal bacteria found in
fecal matter and human identity. One the one hand,
these genomes are clearly not a part of the human gen-
ome and so should not be considered in any way a com-
ponent of ‘being human’. On the other hand, the notion
that the human genome has co-evolved to its present
state with this multitude of bacterial genomes, and that
we require this symbiotic relationship for the mainte-
nance of our health, suggests that the particular collec-
tion of microbial genomes each of us carries may be
almost as personal as our own genome. At present,
there is still much scientific uncertainty about the stabi-
lity of the microbiome over time, so it is unclear
whether a microbial ‘waste’ sample could still be linked
to the individual it came from after a certain number of
years. It is thus pertinent to ask whether ownership is
indeed a relevant consideration if a sample can no
longer be linked back to a certain individual, particularly
if this sample was considered waste in the first place. To
put it another way, if it turns out that a given indivi-
dual’s microbiome changes and evolves over time, does
this make the ownership claim more or less valid?
The issue of ownership is important for two main rea-
sons. The first can broadly be described as having to do
with human dignity, especially as it relates to cultural
identities, and the second with potential consequences
of ownership, particularly financial. Regarding the for-
mer, several parallels can be drawn with biobank
research utilising blood samples. For example, the Nuu-
chah-nulth, an indigenous population on Vancouver
Island, agreed to blood sample collection for genetic
research on rheumatoid arthritis. However, these sam-
ples were later used - without the Nuu-chah-nulth’s
knowledge or consent - for research into their ancestral
origin. This incident was controversial not just because
informed consent was not obtained, but also because of
the cultural importance of blood and sense of ownership
for the Nuu-chah-nulth, who felt that their samples had
been stolen[48]. Although fecal matter can hardly be
described in the way blood has been as the ‘most sym-
bolically precious of substances’[49], it is associated with
deep psychological and cultural significance in other
ways. Collection of vaginal microbiome samples is simi-
larly highly personal and associated with a range of cul-
tural, social, and psychological sensitivities. In short,
collection of microbial samples is potentially highly per-
sonal in ways that are quite different from the sense of
ownership individuals may experience in relation to
other tissue samples. Precisely how this sense of owner-
ship will manifest for research utilising microbial sam-
ples is currently unknown and should itself be the
subject of research sensitive to cultural, religious, and
other contexts.
Regarding the issue of material consequences of own-
ership, the commercial entitlements of ownership
become contentious particularly in discussions of tech-
nology development (for example drug, software and
biotech development) which may lead to economic gain
through intellectual property, sales and marketing,
patenting and so on. Such concerns do have similarities
with ethical issues raised in tissue biobank research,
such as the potential for financial goals to drive research
direction, patenting that either stimulates or stifles tech-
nology and treatment development, and financial benefit
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prietary, particularly when considering publicly funded
research, raise ethical issues such as justice, fairness and
benefit distribution. For example, as derivation of bene-
fit, financial or otherwise, is one consequence of owner-
ship, there is concern that benefits may only be made
available to those who can afford to pay. Benefits of the
research, in the form of novel or improved treatment
modalities or in the form of financial benefit sharing,
may not actually reach those who contributed to
research or those in greatest need. The issue is particu-
larly relevant in a broader international context and the
question of whether and how microbiome research ben-
efits those in developing nations, will need to be consid-
ered[50,51].
These issues are not unique to microbiome studies
but may manifest rather distinctly in this type of
research or its applications. For example, a controversial
method for treating certain forms of bowel disease
involves the use of fecal transplants, in which a slurry of
feces from a healthy donor (usually a close relative of
the patient) is transplanted into the patient. These treat-
ments seem to be extremely efficacious and are based
on the notion that the microbial populations within the
stool of the healthy donor are able to repopulate and
colonise the abnormal gut of the patient and thereby
affect a cure. The treatment is controversial, however, as
the transplant may also introduce any number of patho-
gens to the patient. It is thus only used in very extreme
cases of illness, and most hospitals are reluctant to
allow the procedure at all (interview 140 & interview
116). Work is currently underway to characterise the
efficacious bacteria in a healthy gut on a genomic level,
to isolate them and turn them into a probiotic treatment
that does not require the transplant of fecal matter
(interview 140). The point here is that (i) there is evi-
dent value in the feces of (at least some) individuals,
and that (ii) both the treatment, as well as research per-
taining to the treatment, are likely to be associated with
cultural sensitivities, awkwardness, and possibly embar-
rassment on the part of patients and research partici-
pants. This suggests that serious consideration be given
to questions of ownership as they pertain to human
microbiome derived samples.
Return of results
T h ei s s u eo fw h e t h e r ,h o w ,a n du n d e rw h a tc i r c u m -
stances to return research results to research partici-
pants has been subject to considerable scrutiny both
from the public and research perspectives[26,52-55]. In
biobank and genetic research the question of return of
results usually relates to informing research participants
about genetic predispositions, particularly where treat-
ment options or preventative strategies may be of value
and individuals may act on this information[56]. Some
argue that research participants have a right to know
such information[57,58], whilst others argue that there
is a right not to know[59,60]. Researchers voice con-
cerns that requiring return of results places an unjust
burden on them, making the research enterprise unten-
able[5]. In addition, unless the clinical utility of research
results is firmly established by evidence based studies,
there is a risk of harm due to the premature or inade-
quate translation of research results[61,62].
These debates are equally relevant to microbial
research, and similar questions are raised, including
whether results should be returned on a public or indi-
vidual level and who is responsible for result disclosure
and explanation[23]. It is possible however that return
of microbial research results may actually have more
impact, on an individual and public level, than genetic
research results, if an individual is found to have a
potentially harmful microbial profile that is easily trea-
ted. There has been much debate about the utility of
genetic information, particularly when there is little that
can be done to mitigate such genetic risks[63]. Given
that commensal microbial populations are likely to be
more malleable than human genes, knowledge of an
individual’s microbial profile may open up far more
decisions points for treatment, diagnosis, and risk man-
agement than knowledge of one’sg e n o m e [ 6 4 ] .T h i sh a s
even more profound implications if there is an infec-
tious component to a microbial profile so that return of
research results may be of immediate public health
interest.
Summary
As outlined in our introduction, although there are a
range of ELSI issues raised by human microbiome
research, we have focussed primarily on the intersec-
tion of human microbiome research and biobanking.
Many of the ELSI issues raised by human microbiome
research in this context are not significantly different
from those already encountered in human tissue bio-
bank research. However, there are some areas in which
the already difficult considerations involving privacy,
consent, ownership and return of results are further
complicated by the additional collection and study of
microbial DNA associated with humans. Identifying
these challenges is not intended to hinder microbiome
research, but rather to assist researchers, clinicians,
and patients to work together in ways that build
understanding and cooperation, while avoiding unne-
cessary conflict. Engaging with these challenges at a
relatively early stage of the science also allows mean-
ingful and relevant policy guidelines to be formulated
for human microbiome research and its applications in
ap r o a c t i v er a t h e rt h a nr e a c t i v em a n n e r .
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In considering the rather specific issues of privacy, con-
sent, return of results, and ownership in the context of
research ethics and biobanks, there has been growing
recognition first, that these issues cannot be resolved in
isolation from each other and, second, that their resolu-
tion must involve a strong focus on governance. While
operationalization of standardised approaches to bio-
bank governance are only just beginning to emerge, cur-
rent thinking on the subject tends to emphasise the
need to facilitate health research while enhancing the
capacity for participant and public involvement as well
as benefit sharing[44,65]. This trend is likely to continue
with research endeavours relating to the human micro-
biome, but will inevitably require creative adaptation to
apply to novel circumstances introduced by microbial
research. Moreover, while many human genome
researchers have become accustomed to thinking about
the social and ethical implications associated with their
research, microbial researchers may not have previously
engaged with such issues as the need to protect research
participants’ privacy, and dealing with incidental findings
such as disease predispositions and whether (and how)
to communicate these results back to participants.
Considerations about governance may become even
more pressing and complex with the advent of human
microbiome research due to the public health implica-
tions of such research. For instance, while already com-
plicated, considerations about biobank governance have
generally not had to take into account issues such as
infectious disease. This is clearly an important factor for
microbial research, and mechanisms for interfacing
research platforms with public health agencies will likely
need to be designed. Importantly, this link will need to
be made transparent to research participants to conform
with adequate informed consent criteria.
Justice considerations
In addition, as alluded to in our discussion on owner-
ship and return of results, provisions for benefit sharing
are relevant in this context[50]. The precise form that
benefit sharing might take can vary, but involves ensur-
ing that the results of research are distributed with
some sense of justice and fairness. Benefits of research
can be conceptualised in terms of financial returns,
medical technologies, or public health benefits, while
appropriate beneficiaries might include the researchers,
research participants, funders, identifiable minorities and
the wider public, depending on context. Similar to the
charges of bioprospecting and biopiracy that have been
levelled against some genetic researchers for exploiting
indigenous groups without appropriate compensation,
microbiome research may lend itself to exploitation of
groups and individuals for the benefit of already
privileged segments of the population. For example,
given the importance that is attributed to commensal
bacteria in human health, research is likely to focus on
producing probiotic interventions through studying cor-
relations between particular health variables (e.g., cancer
resistance, immunity, women’s health) and the microbial
profiles of certain individuals or groups. Without appro-
priate governance, the primary health benefit of these
probiotics will flow to those who can afford them, while
the associated financial benefits will flow to researchers
and developers. While there can be no a priori objection
to this, there is a sense of incongruity if the research
participants who contributed time, samples, and exposed
themselves to the potential risks of research involvement
share neither financial nor health benefits.
Recommendations
In conclusion, our consideration of the social and ethical
dimensions of the intersection of human microbiome
research and tissue biobanking suggest some recommen-
dations for policy:
1. We need to be mindful of, and protect against,
novel and unanticipated forms of discrimination that
may arise from microbiome research. Such discrimi-
nation may come in many forms, and be based on
any number of levels of categorization including
socio-economic factors, and cultural or ethnic back-
ground (interview 137). Marginalised sectors of
society who already suffer from discrimination, such
as minorities and those with obesity, may find that
microbiome research leads to a greater ‘scientific’
basis for marginalisation - the results of which could
be abhorrent. Also, association of diseases such as
cancer with a microbial aetiology (whether correct
or incorrect) may lead to stigmatisation of groups
reminiscent of those associated with certain infec-
tious diseases.
2. As with other forms of biomedical research,
microbiome research needs to be sensitive toward
the socio-cultural and economic context of its
research participants. Given the nature of microbial
research on samples sourced from humans, particu-
lar attention should be given to respecting the sensi-
tivities of participants. Success in this regard is likely
to be rewarded with strong research participation,
and stronger relationships of trust between scientists
and the larger public. Failure will inevitably lead
towards further alienation between the scientific
establishment and certain members and subgroups
of the public.
3. As outlined above, microbial data may be as
powerful as genetic information in calculating pre-
dispositions to disease. In addition, knowledge of the
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will certainly provide a far superior platform for cal-
culating disease predispositions. Microbiome
research studies will need to take this into account
and make adequate provision for making decisions
to withhold or disseminate such information to
research participants.
4. Until there is evidence to the contrary, informa-
tion about an individual’s microbiome should be
treated with the same safeguards as human genetic
information. This means that biobanks (whether
they hold biological samples and/or information)
need to make adequate provision for data storage
protection mechanisms to diminish potential privacy
breaches. In this context, the concept of what is
truly ‘personal’ information needs further exploration
and definition. As with other forms of data, privacy
breaches of microbial data have the potential for
harmful effects, infringement of autonomy, stigmati-
zation and discrimination, yet these need to be
balanced with public health considerations. Aware-
ness of these potential outcomes should enable us to
build in adequate privacy protections at the begin-
ning of such research endeavours. Anonymization of
specimens may be an option, however may be mean-
ingless if the sample can be linked back to an identi-
fiable sample elsewhere[27]. In addition,
anonymization of specimens may be less fruitful for
the research endeavor[42].
5. Given that many researchers working on the HMP
have not had previous experience with human sub-
jects research, efforts might be made to increase
awareness among researchers about the social and
ethical implications associated with such research.
6. Finally, the question of ‘who owns your poop?’
will finally need to get the attention it really
deserves. If only to avert costly court cases and mis-
matched expectations between researchers and parti-
cipants, a reconsideration of the categorisation of
human waste may be important.
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